Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omnium Chimique SA
Original Assignee
Omnium Chimique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omnium Chimique SAfiledCriticalOmnium Chimique SA
Publication of FR2222374A1publicationCriticalpatent/FR2222374A1/en
Application grantedgrantedCritical
Publication of FR2222374B3publicationCriticalpatent/FR2222374B3/fr
C07D459/00—Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone
Abstract
N-Substd. indole derivs are prepd. by prepg. 2,3-dihydro-indoles from the starting indoles, substituting these on the N-atom, and dehydrogenating the 2,3-dihdyro-N-substd. indoles. The N-methyl derivs of reserpiline, tetraphylline and raubasine are claimed as new as are some 2,3-dihydro- and N-methyl-dihydro-alkaloid inters. The reactions are carried out by conventional methods. The therapeutic props. of indole derivs are considerably modified by N-substn.